|
Name |
Oxirane-2-carboxylic acid, 3-(3,4,5-trimethoxyphenyl)-, methyl ester
|
Molecular Formula | C13H16O6 | |
IUPAC Name* |
methyl 3-(3,4,5-trimethoxyphenyl)oxirane-2-carboxylate
|
|
SMILES |
COC1=CC(=CC(=C1OC)OC)C2C(O2)C(=O)OC
|
|
InChI |
InChI=1S/C13H16O6/c1-15-8-5-7(6-9(16-2)11(8)17-3)10-12(19-10)13(14)18-4/h5-6,10,12H,1-4H3
|
|
InChIKey |
UAIRDODKPSQSRT-UHFFFAOYSA-N
|
|
Synonyms |
Oxirane-2-carboxylic acid,3-[3,4,5-trimethoxyphenyl]-, methyl ester; 3-(3,4,5-Trimethoxyphenyl)glycidic acid methyl ester; Methyl 3-(3,4,5-trimethoxyphenyl)-2-oxiranecarboxylate; Methyl 3-(3,4,5-trimethoxyphenyl)-2-oxiranecarboxylate #; Oxirane-2-carboxylic acid, 3-(3,4,5-trimethoxyphenyl)-, methyl ester
|
|
CAS | NA | |
PubChem CID | 602508 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 268.26 | ALogp: | 1.3 |
HBD: | 0 | HBA: | 6 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.599 |
Caco-2 Permeability: | -4.682 | MDCK Permeability: | 0.00004370 |
Pgp-inhibitor: | 0.593 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.229 |
Blood-Brain-Barrier Penetration (BBB): | 0.988 | Plasma Protein Binding (PPB): | 35.81% |
Volume Distribution (VD): | 0.615 | Fu: | 34.90% |
CYP1A2-inhibitor: | 0.063 | CYP1A2-substrate: | 0.954 |
CYP2C19-inhibitor: | 0.1 | CYP2C19-substrate: | 0.913 |
CYP2C9-inhibitor: | 0.024 | CYP2C9-substrate: | 0.496 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.818 |
CYP3A4-inhibitor: | 0.043 | CYP3A4-substrate: | 0.684 |
Clearance (CL): | 7.4 | Half-life (T1/2): | 0.659 |
hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.354 |
Drug-inuced Liver Injury (DILI): | 0.44 | AMES Toxicity: | 0.208 |
Rat Oral Acute Toxicity: | 0.154 | Maximum Recommended Daily Dose: | 0.034 |
Skin Sensitization: | 0.196 | Carcinogencity: | 0.052 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.052 |
Respiratory Toxicity: | 0.116 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000340 | 0.453 | D0AO5H | 0.358 | ||||
ENC001396 | 0.381 | D0D4HN | 0.356 | ||||
ENC005523 | 0.381 | D0A8FB | 0.354 | ||||
ENC001423 | 0.381 | D09DHY | 0.347 | ||||
ENC005931 | 0.379 | D02LZB | 0.337 | ||||
ENC005937 | 0.371 | D01FFA | 0.313 | ||||
ENC001577 | 0.368 | D0Y7TS | 0.309 | ||||
ENC001410 | 0.368 | D09HDR | 0.305 | ||||
ENC005935 | 0.367 | D06GCK | 0.301 | ||||
ENC005977 | 0.363 | D0C1SF | 0.300 |